These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 15500142)

  • 21. Reversal of the nephrotic syndrome due to renovascular hypertension by successful percutaneous angioplasty and stenting.
    Ben-Chitrit S; Korzets Z; Podjarny E; Bernheim J
    Nephrol Dial Transplant; 1995; 10(8):1460-1. PubMed ID: 8538946
    [No Abstract]   [Full Text] [Related]  

  • 22. [Nephrotic syndrome and renal artery stenosis].
    Bello I; Navas J; Morales JM; Alcázar JM; Barrientos A; Rodicio JL
    Med Clin (Barc); 1983 May; 80(17):762-4. PubMed ID: 6621126
    [No Abstract]   [Full Text] [Related]  

  • 23. Long-term effects of candesartan and amlodipine on cardiovascular morbidity and mortality in Japanese high-risk hypertensive patients: the Candesartan Antihypertensive Survival Evaluation in Japan Extension Study (CASE-J Ex).
    Ogihara T; Ueshima K; Nakao K; Fukiyama K; Oba K; Yasuno S; Fujimoto A; Sato T; Matsuoka H; Saruta T;
    Hypertens Res; 2011 Dec; 34(12):1295-301. PubMed ID: 21833000
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney diseases and are treated with angiotensin-converting enzyme inhibitors.
    Kanno Y; Takenaka T; Nakamura T; Suzuki H
    Clin J Am Soc Nephrol; 2006 Jul; 1(4):730-7. PubMed ID: 17699280
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nephrotic-range proteinuria in a patient with high renin hypertension: effect of treatment with an ACE-inhibitor.
    Docci D; Moscatelli G; Capponcini C; Baldrati L; Feletti C
    Am J Nephrol; 1992; 12(5):387-9. PubMed ID: 1489013
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A case of nephrotic syndrome associated with renovascular hypertension successfully treated with candesartan.
    Takahashi F; Hasebe N; Chinda J; Okada M; Takeuchi T; Hirayama T; Imamoto C; Kikuchi K
    Hypertens Res; 2003 Jan; 26(1):123-7. PubMed ID: 12661922
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of renin-angiotensin system blockade on macrophage infiltration in patients with hypertensive nephrosclerosis.
    Imakiire T; Kikuchi Y; Yamada M; Kushiyama T; Higashi K; Hyodo N; Yamamoto K; Oda T; Suzuki S; Miura S
    Hypertens Res; 2007 Jul; 30(7):635-42. PubMed ID: 17785932
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The angiotensin II receptor antagonist candesartan is not effective in reducing portal hypertension in patients with cirrhosis.
    Heim MH; Jacob L; Beglinger C
    Digestion; 2007; 75(2-3):122-3. PubMed ID: 17630472
    [No Abstract]   [Full Text] [Related]  

  • 30. Role of diabetes and obesity in outcomes of the candesartan antihypertensive survival evaluation in Japan (CASE-J) trial.
    Nakao K; Hirata M; Oba K; Yasuno S; Ueshima K; Fujimoto A; Ogihara T; Saruta T;
    Hypertens Res; 2010 Jun; 33(6):600-6. PubMed ID: 20379187
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of an ARB on endothelial progenitor cell function and cardiovascular oxidation in hypertension.
    Yu Y; Fukuda N; Yao EH; Matsumoto T; Kobayashi N; Suzuki R; Tahira Y; Ueno T; Matsumoto K
    Am J Hypertens; 2008 Jan; 21(1):72-7. PubMed ID: 18091747
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Severe hypertension and nephrotic syndrome].
    Lambert M; Cosyns JP; de Plaen JF; Pochet JM; Michaux L; Pirson Y
    Nephrologie; 1993; 14(2):105-12. PubMed ID: 8327027
    [No Abstract]   [Full Text] [Related]  

  • 33. [A case of renovascular hypertension with nephrotic syndrome, accompanied by focal segmental glomerulosclerosis-like lesion in the contralateral kidney].
    Fujii S; Kasahara H; Oguchi H
    Nihon Jinzo Gakkai Shi; 1991 Oct; 33(10):1017-24. PubMed ID: 1770622
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The Heart Institute of Japan--candesartan randomized trial for evaluation in CAD (HUJ-CREATE)].
    Hagiwara N; Ogawa H; Kasanuki H
    Nihon Rinsho; 2011 Nov; 69 Suppl 9():551-3. PubMed ID: 22724261
    [No Abstract]   [Full Text] [Related]  

  • 35. Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis--a randomized study.
    Takahashi A; Takase H; Toriyama T; Sugiura T; Kurita Y; Ueda R; Dohi Y
    Nephrol Dial Transplant; 2006 Sep; 21(9):2507-12. PubMed ID: 16766543
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Letter: Nephrotic syndrome due to nephrosclerosis?].
    Buchborn E
    Dtsch Med Wochenschr; 1974 Jul; 99(27):1475. PubMed ID: 4843508
    [No Abstract]   [Full Text] [Related]  

  • 37. [Anti-metabolic syndrome effects of candesartan].
    Yamauchi T; Kadowaki T
    Nihon Rinsho; 2009 Feb; 67(2):408-16. PubMed ID: 19202920
    [No Abstract]   [Full Text] [Related]  

  • 38. Angiotensin receptor blockade in diabetic renal disease--focus on candesartan.
    García Donaire JA; Ruilope LM
    Diabetes Res Clin Pract; 2007 May; 76 Suppl 1():S22-30. PubMed ID: 17339065
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treating prehypertension.
    Grassi DG
    N Engl J Med; 2006 Jul; 355(4):416; author reply 417-8. PubMed ID: 16870923
    [No Abstract]   [Full Text] [Related]  

  • 40. Aldosterone breakthrough during angiotensin II receptor blockade in hypertensive patients with diabetes mellitus.
    Yoneda T; Takeda Y; Usukura M; Oda N; Takata H; Yamamoto Y; Karashima S; Yamagishi M
    Am J Hypertens; 2007 Dec; 20(12):1329-33. PubMed ID: 18047925
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.